Key result
Pre-PCI atorvastatin cuts 48-hour NLR ~35% vs. rosuvastatin in STEMI.
Why the study?
Does pre-procedural atorvastatin compared to rosuvastatin improve hematologic and inflammatory markers in STEMI patients undergoing primary PCI?
RCT (n=200)
triple-blind
randomized
Yes
Does pre-procedural atorvastatin compared to rosuvastatin improve hematologic and inflammatory markers in STEMI patients undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
Pre-procedural atorvastatin 80 mg demonstrates a more pronounced anti-inflammatory effect than rosuvastatin 40 mg in STEMI patients undergoing primary PCI, despite similar rates of contrast-induced nephropathy.
Background The pleiotropic effects of statins may benefit patients with acute coronary syndromes. This study compared the impact of pre-procedural atorvastatin versus rosuvastatin on hematologic and inflammatory indexes in the hyper-acute setting of ST-elevation myocardial infarction (STEMI). Methods In this pre-specified, multi-centric, triple-blind trial, STEMI patients were randomized to receive either 80-mg atorvastatin ( n = 98) or 40-mg rosuvastatin ( n = 102) before primary percutaneous coronary intervention (PPCI). Key hematologic indexes—neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet distribution width (PDW)—were measured at baseline, 24, and 48 h post-PPCI. Contrast-induced nephropathy (CIN) incidence was also assessed. Results The incidence of CIN was similarly low in both groups (atorvastatin 3.0 % vs. rosuvastatin 3.5 %, p = 0.99). However, hematologic markers showed significant differences. The atorvastatin group had a significantly lower NLR at 48 h compared to the rosuvastatin group (Median [IQR]: 5.1 [3.2–8.1] vs. 7.8 [4.9–10.2], p = 0.003). Conversely, the rosuvastatin group demonstrated a significantly higher PDW at 24 h (15.6 ± 1.5 vs. 14.7 ± 1.5, p < 0.001). No significant inter-group difference was found in the 48-h PLR. Conclusion While both high-intensity statins provided similar nephroprotection, they exhibited distinct modulatory effects. Atorvastatin was associated with a more pronounced anti-inflammatory effect (lower NLR), whereas rosuvastatin was linked to increased platelet activity (higher PDW). These findings suggest differential pleiotropic properties that warrant further investigation for their impact on clinical outcomes. Registry Accessibility: http://irct.ir/trial/27377 Trial registration code: IRCT2017101236737N1.
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted an RCT in ST-elevation myocardial infarction (STEMI) (n=200). Atorvastatin vs. Rosuvastatin 40-mg was evaluated on Neutrophil-to-lymphocyte ratio (NLR) at 48 h (p=0.003). Pre-procedural atorvastatin resulted in a lower neutrophil-to-lymphocyte ratio at 48 hours compared to rosuvastatin in STEMI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: